Immutep Ltd is a leading biotechnology company that focuses on developing novel immunotherapeutic treatments. The company is dedicated to improving the lives of patients with cancer and autoimmune diseases through innovative research and development. Immutep's core values revolve around scientific excellence, integrity, and patient-centricity. With a commitment to advancing cutting-edge therapies, Immutep embraces a corporate philosophy centered on collaboration, innovation, and delivering breakthrough solutions. By harnessing the power of the immune system, Immutep aims to revolutionize the way diseases are treated, offering hope and improved outcomes to patients worldwide.

Immutep Ltd is primarily present in several countries and regions worldwide. These include Australia, where the company is headquartered, as well as the United States, Europe, and Asia-Pacific. With a focus on developing novel immunotherapy treatments, Immutep Ltd has established a global presence to reach patients and collaborate with healthcare and bio-pharmaceutical partners across these regions.

Immutep Ltd, a leading biotechnology company, has achieved several significant milestones. Firstly, the company successfully completed a Phase IIb clinical trial for its flagship product, Eftilagimod Alpha (efti). The trial demonstrated promising results in treating metastatic breast cancer. Secondly, Immutep entered into a strategic collaboration with major pharmaceutical companies to further develop and commercialize efti. This collaboration enhances its growth potential and market reach. Additionally, Immutep received Fast Track designation from the U.S. FDA for efti, expediting its regulatory process. These accomplishments showcase Immutep Ltd's dedication to advancing breakthrough immunotherapies and solidify its position in the biotech industry.

Immutep Ltd is an Australian biotechnology company specializing in developing immunotherapy treatments for cancer and autoimmune diseases. Established in 2001, Immutep has a rich history of pioneering research and significant advancements in the field of immune-based therapies. The company's extensive expertise lies in the development of its lead product candidate, eftilagimod alpha (efti), a soluble LAG-3 protein aimed at enhancing immune responses. Immutep Ltd has collaborated with renowned pharmaceutical companies and research institutions worldwide, reinforcing its dedication to advancing immunotherapy and ultimately improving patient outcomes. With a strong focus on innovation, Immutep continues to make significant contributions in the immunotherapy space, propelling the fight against cancer and autoimmune diseases forward.

The main competitors of Immutep Ltd in the market include companies like Bristol-Myers Squibb, AstraZeneca, Merck, Roche, and Novartis. These companies also operate in the biopharmaceutical sector and focus on developing innovative treatments and therapies. Immutep Ltd differentiates itself through its unique therapeutic pipeline and commitment to the development of immunotherapies. With their focus on immunomodulation and immuno-oncology, Immutep Ltd aims to make a significant impact in the field of cancer treatment and autoimmune diseases, setting itself apart from its competitors.

Immutep Ltd is primarily active in the biotechnology and healthcare industries.

The business model of Immutep Ltd revolves around developing and commercializing immunotherapy treatments. Immutep Ltd focuses on the development of LAG-3 related products, which play a crucial role in regulating the immune system. By leveraging its expertise and technology, the company aims to treat a wide range of diseases, including cancer and autoimmune disorders. Immutep Ltd collaborates with various partners and conducts clinical trials to evaluate the safety and effectiveness of its therapies. Through strategic partnerships and licensing agreements, the company aims to bring its innovative treatments to market, ultimately improving patient outcomes and advancing the field of immunotherapy.

Коефициентът на цена спрямо печалбата (КЦП) на Immutep е -6,16.

Коефициентът на цена към оборот (KUV) на Immutep е 73,53.

AlleAktien качественият резултат за Immutep е 5/10.

очаквана Immutep оборотът е 4,04 млн. AUD.

очаквана Immutep печалба е -48,29 млн. AUD.

Immutep Ltd is an Australian biotechnology company specializing in the development of immunotherapies for the treatment of cancer and autoimmune diseases. The company has two main product platforms, the Lymphocyte Activation Gene (LAG)-3 platform and the IMP321 platform. Its leading products are IMP321, an agonistic LAG-3 antibody, and eftilagimod alpha, an IMP321-based immunotherapy. Immutep also offers services for preclinical and clinical development of immunotherapies. The company has partnerships with pharmaceutical companies such as Novartis, GlaxoSmithKline, and Eddingpharm. It has a portfolio of patents and intellectual property in the LAG-3 and IMP321 areas, and has licensed its LAG-3 technology for predictive diagnostics in cancer patients. Overall, Immutep aims to research, develop, and market immunotherapies for the treatment of cancer and autoimmune diseases, as well as provide services for their development. It positions itself as a leading provider of immunotherapies based on LAG-3 and IMP321 technologies. The answer: Immutep Ltd is an Australian biotechnology company specializing in the development of immunotherapies for the treatment of cancer and autoimmune diseases. It has two main product platforms, LAG-3 and IMP321. Leading products include IMP321 and eftilagimod alpha. The company also offers services for preclinical and clinical development of immunotherapies. It has partnerships with Novartis, GlaxoSmithKline, and Eddingpharm. Immutep has patents and intellectual property in the LAG-3 and IMP321 areas. It has licensed its LAG-3 technology for predictive diagnostics in cancer patients. Overall, Immutep aims to research, develop, and market immunotherapies for cancer and autoimmune diseases, as well as provide development services. It positions itself as a leading provider of immunotherapies based on LAG-3 and IMP321 technologies.

Immutep разпределя дивидента от 0 AUD на плащания годишно.

Дивидентата за Immutep в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Immutep е AU000000IMM6.

WKN на Immutep е A2H81H.

Тикерът на Immutep е IMM.AX.

През последните 12 месеца Immutep изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Immutep да изплати дивиденда в размер на 0 AUD.

Дивидентната доходност на Immutep в момента е .

Immutep изплаща дивидент на тримесечие. Той се разпределя в месеците .

Immutep платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 AUD. Това съответства на дивидентна доходност от 0 %.

Immutep се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Immutep на 29.07.2024 г. в размер на 0 AUD, трябваше да притежавате акцията в портфейла си преди Ex-деня на 29.07.2024 г..

Последното дивидентно плащане беше извършено на 29.07.2024 г..

През година 2023 Immutep изплати 0 AUD под формата на дивиденти.

Дивидентите от Immutep се изплащат в AUD.